NCT05364879 Prehabilitation for Ovarian Cancer Patients
| NCT ID | NCT05364879 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Nova Scotia Health Authority |
| Condition | Prehabilitation |
| Study Type | INTERVENTIONAL |
| Enrollment | 108 participants |
| Start Date | 2023-01-03 |
| Primary Completion | 2027-08-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 108 participants in total. It began in 2023-01-03 with a primary completion date of 2027-08-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Individuals with ovarian cancer have very poor survival rates. This is because the cancer is not usually detected until it has reached advanced stages. How long an individual survives also is determined by the cancer treatment they receive. Although there are best treatment practices to improve survival, some women have other conditions that limit treatment options. One such condition seen in as many as 50% of women with advanced ovarian cancer is frailty (an age-related decline in function and health). This is a major concern as doctors will often have to change how the cancer is treated based on the patient being frail. For example, patients living with frailty are less likely to have their full tumor removed during surgery. They are also more likely to have complications with surgery, stay in the hospital longer, and recover less well from surgery overall. Patients living with frailty also are more likely to experience delays in their chemotherapy starting, receive lower doses of chemotherapy and/or receive fewer cycles of chemotherapy. These changes in treatment may decrease how long a patient survives after diagnosis. Thus, research is needed to explore strategies to decrease frailty in patients who require treatment for advanced ovarian cancer. An option gaining more attention is physical exercise (e.g. walking, repeatedly rising from a chair). Exercise performed before surgery, which is called prehabilitation, can improve how well a patient recovers after surgery and increase how long they survive. Research has shown that prehabilitation is very beneficial for patients undergoing surgery for heart disease. However, it is not clear whether prehabilitation works for those with advanced ovarian cancer that are going to have surgery. Therefore, the investigators want to explore how a 4+ week exercise program performed while waiting for surgery for advanced ovarian cancer changes frailty and how a patient recovers after surgery. The investigators will specifically look whether the exercise program: 1) reduces how frail a patient is before surgery; 2) improves how well the patient recovers after surgery; and 3) affects the patient's chemotherapy treatment plan. This study will provide important information about the ability of prehabilitation exercise to improve surgical and treatment outcomes in women with advanced ovarian cancer. Overall, it is believed that exercise has the potential to improve the survival of advanced ovarian cancer patients.
Eligibility Criteria
Inclusion Criteria: * 18 years or older * Have a confirmed diagnosis of stage III or IV ovarian cancer * Scheduled to receive cytoreductive surgery as part of their treatment plan * Must have a minimum of 4-weeks between the time of study enrollment and scheduled surgery * Be able to attend in-person and/or virtual exercise sessions * Be fluent in English * Have oncologist approval Exclusion Criteria: * Have already completed surgery * Unstable cardiac or respiratory disease, injury or any other co-morbid disease that may make it unsafe for participants to exercise * Significant cognitive impairment (e.g., do not have the capacity to consent, unable to follow exercise instructions)
Contact & Investigator
Scott Grandy, PhD
PRINCIPAL INVESTIGATOR
Nova Scotia Health
Frequently Asked Questions
Who can join the NCT05364879 clinical trial?
This trial is open to female participants only, aged 18 Years or older, studying Prehabilitation. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05364879 currently recruiting?
Yes, NCT05364879 is actively recruiting participants. Contact the research team at grandy@dal.ca for enrollment information.
Where is the NCT05364879 trial being conducted?
This trial is being conducted at Halifax, Canada.
Who is sponsoring the NCT05364879 clinical trial?
NCT05364879 is sponsored by Nova Scotia Health Authority. The principal investigator is Scott Grandy, PhD at Nova Scotia Health. The trial plans to enroll 108 participants.